Abbvie Inc.

Abbvic Inc.

Abbvie Ireland Unlimited Company

Amit Khatri

Sandeep Dutta

Cheri E Klein

Walid M Awni

Barry M Bernstein

Daniel E Cohen

Sven Mensing

Rajeev M Menon

Thomas J Podsadecki

Emily O Dumas

Scott C Brun

The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.

Methods for treating HCV

The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).

Growing community of inventors

Waukegan, IL, United States of America

Amit Khatri